BiotechTube
Pinion Immunotherapeutics

Pinion Immunotherapeutics

Cambridge, United States· Est.
pinionimt.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

Pinion Immunotherapeutics is a privately held, preclinical-stage biotech leveraging an integrated AI and mRNA/LNP platform to create immunotherapies for viral diseases and cancers. Founded in 2021 and operating as a lean, virtual company, it focuses on capital-efficient development of treatments for large markets lacking curative options. Its leadership team combines deep expertise in vaccine development, immunology, and clinical oncology, aiming to achieve functional cures through dual immune activation.

OncologyInfectious Disease

Technology Platform

Proprietary AI-driven mRNA platform with engineered LNP delivery for dual activation of CD8+ T cells and virus-neutralizing antibodies.

Funding History

1
Total raised:$5.5M
Seed$5.5M

Opportunities

Large, underserved markets for chronic viral infections and virus-driven cancers where current treatments are not curative.
The dual-mechanism (T cell + antibody) approach could provide a differentiated and more effective therapeutic profile, potentially enabling functional cures.

Risk Factors

High preclinical scientific risk; unproven platform in humans.
Intense competition in mRNA and immunotherapy spaces.
Execution risk as a virtual company managing multiple early programs.
Dependence on securing near-term financing (Series A) to advance.

Competitive Landscape

Competes with large mRNA players (e.g., Moderna, BioNTech) and oncology/vaccine-focused biotechs in HPV, AML, and antiviral spaces. Differentiation hinges on AI-optimized antigen selection and engineered LNP delivery aimed at superior dual immune activation compared to conventional vaccines.

More companies in mRNA Therapeutics →More companies in United States →